Skip to main content

Pizza and Rheumatoid Arthritis (8.11.2023)

Dr. Jack Cush reviews the news and journal reports from the wonderful wide world of Rheumatology. This week:

  1. Swedish study of 325 #AAV pts saw CVA in 35 pts (8%); CVA incidence=11.3/1000 PYs - this was higher than gen population [SIR 1.85). AAV CVA risk factors included age <65 yrs (SIR 3.19) & Hi platelet count (HR 1.14), but no effx on survival

  2. Anti-gephyrin autoantibodies (AGA) have been tied to lower GI dysfunction. Johns Hopkins study of 188 scleroderma pts found 8.5% w/ anti-gephyrin Abs (1/4 it was only autoAb). AGA+ assoc w/ severe constipation (46 vs 15%) & bloating (54 vs 25%)

  3. Retrospective study of 1,516 MIS-C pts at 44 sites: 13% received anakinra alone or with other agents as initial treatment. Variable effx w/ anakinra - which was not equivalent to IVIG or steroids vs. IVIG plus steroids (re: vasopressors, LVEF, or CRP

  4. Network Meta-Analysis of Perioperative Pain Control compared gabapentin & pregabalin; finds GABA 900-1200mg/daily before spine surgery assoc w/ lowest pain scores & least opioid use. GABA 3 fold better than pregabalin (75-300). (27 RCTs, 1861 pts)

  5. Prospective, open-label study compared 19 Takayasu pts on secukinumab vs 34 pts on TNFi . SEC response (Complete/partial) was 53% & the TNFi response was 59% at 3 mos. SEC had 4 pts relapse by wk 48 (median 31 wks(, TNFi had 12 pts relapse.

  6. Study of 3082 pts w/ muscle disease; 14 had adult IIM w/ myocarditis. Mean: 54 yrs, 71% black,  Antisynthetase syndrome in 64% (Jo1=4, PL12=3); 79% w/ active myositis, 93% hosp); 5 yr myocarditis survival 53% (6 died; all w/ LVEF < 40%)

  7. IMMpulse study - 1 yr OL, phase 4 trial of risankizumab (150 mg, wk 0, 4) vs apremilast (30 mg bid) in 352 pts w/ moderate plaque psoriasis. RIZ had superior efficacy at wk 16 w/ PASI90 score of 55.9% vs 5.1% for APR.

  8. Cross-sectional study 365 RA pts showed eating half a pizza >1 time/wk (vs. ≤2 times/mo) was assoc w/ 70% less Dz activity; esp w/ more severe RA (80%) (benefit likely due to mozzarella & olive oil). YES, this was an italian study...

  9. Italian JAKi study, 685 pts Rx w/ BARI (48%), TOFA (31%), UPA (14%), filgotinib (7%), had half (47%) Rx JAKi as 1st line, prior to a biologic. AE of special interest (1137 PYs FU) in 18%, including 1 CVA, 3 deaths/infx. High CV risk pts = Hi AESI(23%)

  10. Chinese study of 5530 RA pts found 546 (9.9%) who developed diabetes. DM risk was significantly lower w/ bDMARD (HR 0.51), MTX (HR 0.50) and HCQ (HR 0.52). TNF inhibitors were also protective (HR 0.69).

  11. Metanalysis of remote Pt monitoring w/ electronic Outcome Measures (ePROMs) in #RA (4,473 pts, 7 studies) showed lower disease activity & higher remission rates in ePROM group (OR 1.65) & fewer F2F visits were needed in ePROM grp

  12. Patient Perspectives on Telemedicine Use During the Pandemic

  13. Colchicine or Prednisone in CPPD?   

  14. "Ask Cush Anything" 

  15. RheumNow’s Poster Hall


If you are a health practitioner, you may to comment.

Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.

The author has no conflicts of interest to disclose related to this subject